Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

ludc webb

Harry Björkbacka

Researcher

ludc webb

Immune responses against oxidized LDL as possible targets for prevention of atherosclerosis in systemic lupus erythematosus

Author

  • Ingrid Yao Mattisson
  • Sara Rattik
  • Harry Björkbacka
  • Irena Ljungcrantz
  • Manuela Terrinoni
  • Michael Lebens
  • Jan Holmgren
  • Gunilla Nordin Fredrikson
  • Birgitta Gullstrand
  • Anders A. Bengtsson
  • Jan Nilsson
  • Maria Wigren

Summary, in English

Patients suffering from systemic lupus erythematosus (SLE) are at increased risk of developing cardiovascular disease (CVD) and traditional therapies including statins provide insufficient protection. Impaired removal of apoptotic material is a common pathogenic mechanism in both SLE and atherosclerosis and is considered to be a key factor in the development of autoimmunity. Since oxidized LDL and apoptotic material bind to the same receptors, we aimed to investigate if targeting the oxidized LDL autoimmunity can affect atherosclerosis in SLE. To investigate the possible role of oxidized LDL autoimmunity in the accelerated atherosclerosis associated with SLE we used a hypercholesterolemic SLE mouse model (B6.lpr.ApoE−/− mice). Promoting LDL tolerance through mucosal immunization with an apolipoprotein B-100 peptide p45 (amino acids 661–680) and cholera toxin B-subunit fusion protein increased regulatory T cells and B cells in mesenteric lymph nodes and reduced plaque development in the aorta by 33%. Treatment with the oxidized LDL-specific antibody Orticumab reduced aortic atherosclerosis by 43%, subvalvular plaque area by 50% and the macrophage content by 31%. The present study provides support for oxLDL as a possible target for prevention of cardiovascular complications in SLE.

Department/s

  • Cardiovascular Research - Immunity and Atherosclerosis
  • Cardiovascular Research - Cellular Metabolism and Inflammation
  • EXODIAB: Excellence in Diabetes Research in Sweden
  • Lund SLE Research Group
  • EpiHealth: Epidemiology for Health

Publishing year

2021-10-01

Language

English

Publication/Series

Vascular Pharmacology

Volume

140

Document type

Journal article

Publisher

Elsevier

Topic

  • Cardiac and Cardiovascular Systems

Keywords

  • Atherosclerosis
  • Autoimmunity
  • oxLDL
  • Systemic lupus erythematosus
  • Vaccine

Status

Published

Research group

  • Cardiovascular Research - Immunity and Atherosclerosis
  • Cardiovascular Research - Cellular Metabolism and Inflammation
  • Lund SLE Research Group

ISBN/ISSN/Other

  • ISSN: 1537-1891